Amgen’s Galimi Jumps to Adicet Bio to Become Chief Medical Officer

Xconomy San Francisco — 

Francesco Galimi has been appointed senior vice president and chief medical officer of Adicet Bio. Galimi comes to the Menlo Park, CA-based cancer drug developer from Amgen (NASDAQ: AMGN), where he was global program general manager of early development. His experience also includes positions at Onyx Pharmaceuticals and the Genomics Institute of the Novartis Research Foundation. Preclinical-stage Adicet is developing allogeneic, or “off-the-shelf,” cancer cell therapies.